Patient-Led Skin Cancer Teledermatology without Dermoscopy during the Covid pandemic: Important lessons for the development of future patient-facing teledermatology & AI-assisted self-diagnosis.

MySkinSelfie was a mobile phone application for skin self-monitoring enabling secure sharing of patient-captured images with healthcare providers. This retrospective study assessed MySkinSelfie's role in remote skin cancer assessment at two centres for urgent (melanoma & squamous cell carcinoma) and non-urgent skin cancer referrals, investigating the feasibility of using patient-taken images without dermoscopy for remote diagnosis. Total number of lesions utilising MySkinSelfie was 814 with mean age of 63. Remote consultations reduced face-to-face appointments by 90% for basal cell carcinoma and 63% for two-week-wait referrals. Diagnostic concordance (consultant vs histological diagnosis) rates of 72% and 83% were observed for basal cell carcinoma (n=107) and urgent skin cancers (n=704), respectively. Challenges included image quality, workflow integration and lack of dermoscopy. Higher sensitivities have been observed in recent Artificial Intelligence (AI) algorithms employing dermoscopy. While patient-taken images proved useful during the pandemic, further research is needed to explore the feasibility of widespread patient-led dermoscopy to enable direct patient-to-AI diagnostic assessment.

How MFN clauses used in the health care industry unreasonably restrain trade under the Sherman Act.

When used in the health care industry, an MFN clause is a contractual agreement that guarantees a health insurer the same best price as their market competitors. MFN clauses have the effect of unnecessarily raising consumer costs, reducing choice among providers, constraining access to care and preventing the development of alternative health care delivery models. The purpose of this paper is four-fold. First, to design a four-quadrant matrix to evaluate the pro-competitive and anticompetitive purposes and effects of MFN clauses under Section 1 of the Sherman Act. Second, to defeat the jurisprudential presumption that MFN clauses are pro-competitive in the health care industry and to recommend that this presumption be abolished. Third, to examine the U.S. Department of Justice's paradigmatic shift over the last decade toward prosecuting large insurers who employ MFN clauses resulting in U.S. Consent Decrees. Fourth, to outline the indicia of a meritorious claim against an insurer who employs an MFN clause.